Efficacy and Safety of Dupilumab vs Narrowband UVB for the Treatment of Chronic Hand Dermatitis: A Retrospective Study

Christoffers WA, Coenraads PJ, Svensson Å, Diepgen TL, Dickinson‐Blok JL, Xiaet J, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019; 4: CD004055.

https://doi.org/10.1002/14651858.CD004055.pub2 DOI: https://doi.org/10.1002/14651858.CD004055.pub2

Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermat 2022; 86: 357-378.

https://doi.org/10.1111/cod.14035 DOI: https://doi.org/10.1111/cod.14035

Coenraads PJ. Hand eczema. N Engl J Med 2012; 367: 1829-1837.

https://doi.org/10.1056/NEJMcp1104084 DOI: https://doi.org/10.1056/NEJMcp1104084

Ho JSS, Molin S. A Review of Existing and New Treatments for the Management of Hand Eczema. J Cutan Med Surg 2023; 27: 493-503.

https://doi.org/10.1177/12034754231188325 DOI: https://doi.org/10.1177/12034754231188325

Rosén K, Mobacken H, Swanbeck G. Chronic eczematous dermatitis of the hands: a comparison of PUVA and UVB treatment. Acta Derm Venereol 1987; 67: 48-54.

https://doi.org/10.2340/00015555674854 DOI: https://doi.org/10.2340/00015555674854

Nordal E, Christensen O. Treatment of chronic hand dermatoses with UVB-TL01. Acta Derm Venereol 2004; 84: 302-304.

https://doi.org/10.1080/00015550410025886 DOI: https://doi.org/10.1080/00015550410025886

Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed 2007; 23: 10-14.

https://doi.org/10.1111/j.1600-0781.2007.00258.x DOI: https://doi.org/10.1111/j.1600-0781.2007.00258.x

Ruzicka T, Lynde CW, Jemec GBE, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158: 808-817.

https://doi.org/10.1111/j.1365-2133.2008.08487.x DOI: https://doi.org/10.1111/j.1365-2133.2008.08487.x

Lee N, Chipalkatti N, Zancanaro P, Kachuk C, Dumont N, Rosmarin D. A Retrospective Review of Dupilumab for Hand Dermatitis. Dermatology 2019; 235: 187-188.

https://doi.org/10.1159/000496481 DOI: https://doi.org/10.1159/000496481

Loman L, Diercks GF, Schuttelaar ML. Three cases of non‐atopic hyperkeratotic hand eczema treated with dupilumab. Contact Dermat 2021; 84: 124‐127.

https://doi.org/10.1111/cod.13693 DOI: https://doi.org/10.1111/cod.13693

Olesen CM, Yüksel YT, Zachariae C, Lund TT, Agner T, Petersen TS, et al. Treatment of chronic hand eczema with dupilumab-A retrospective follow-up study. J Eur Acad Dermatol Venereol 2023; 37: e557-e559.

https://doi.org/10.1111/jdv.18805 DOI: https://doi.org/10.1111/jdv.18805

Voorberg AN, Kamphuis E, Christoffers WA, Schuttelaar MLA. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol 2023; 189: 400-409.

https://doi.org/10.1093/bjd/ljad156 DOI: https://doi.org/10.1093/bjd/ljad156

Simpson EL, Silverberg JI, Worm M, Honari G, Masuda K, Sygula E, et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. JAAD 2024; 90: 1190-1199.

https://doi.org/10.1016/j.jaad.2023.12.066 DOI: https://doi.org/10.1016/j.jaad.2023.12.066

Paganini C, Maffei V, Vellucci L, Talamonti M, Petruzzellis A, Le Pera L, et al. Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study. J Clin Med 2024; 13: 1876.

https://doi.org/10.3390/jcm13071876 DOI: https://doi.org/10.3390/jcm13071876

Halling AS, Zachariae C, Thyssen JP. Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab. Contact Dermatitis 2020; 83: 37-38.

https://doi.org/10.1111/cod.13501 DOI: https://doi.org/10.1111/cod.13501